Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Lung Cancer Screening and Approach to the Lung Nodule

Brigham and Women's Hospital

A. Ramaswamy

Lung Cancer Screening

Kyle Hogarth

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

Metaphorical Signs in Computed Tomography of Chest

Atul C. Mehta

The Non-Invasive Diagnosis of Lung Cancer

Memorial Sloan Kettering Cancer Center

G. Rocco

Nodules and Lung Cancer Screening

Fox Chase Cancer Center

R. Kumar

Drug Induced Interstitial Lung Disease in Lung Cancer

Society for Advanced Bronchoscopy

A. Abdul Hameed

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

Thoracic Malignancies From an Interventional Pulmonologist's Perspec…

Fox Chase Cancer Center

C. Manley

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

An Overview of Pulmonary Infections in Cancer Patients

International Cancer Imaging Society (ICIS)

L. Frank

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

FDA Approval of Zenocutuzumab for Advanced NRG1 Fusion-Positive NSCL…

Memorial Sloan Kettering Cancer Center

A. Schram

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth